Site Search

The drug company Corbus Pharmaceuticals will start its next Phase 2 clinical trial to test a potential inflammation-targeting drug in people with cystic fibrosis in the first quarter of 2018.

Icagen Inc. will focus on drug discovery, screening for compounds that could suppress nonsense mutations, and using computer modeling to identify molecules that are suitable to be developed into drugs.

Today, the Cystic Fibrosis Foundation announced a collaboration with Deep Science Ventures to accelerate treatments that address the underlying cause of CF for every person with the disease. The collaboration will focus on uncovering and designing new technologies to address key scientific challenges on the Path to a Cure.

This week, Congress approved a budget resolution that will allow lawmakers to make certain changes to the Affordable Care Act and Medicaid.

The Cystic Fibrosis Lung Transplant Consortium Biorepository and Patient Registry, in collaboration with Cleveland Clinic, will provide critical clinical data and samples to support future research investigating complications of lung transplant.

Potential oral formulation of drug targeting nontuberculous mycobacteria infections could reduce side effects of current treatment 

Nonprofit issues challenge to accelerate treatments for every person with CF

Today, the Cystic Fibrosis Foundation announced that it has awarded up to $400,000 to Life Edit Therapeutics Inc. to explore the application of their unique gene editing technology in CF.

Today, the Cystic Fibrosis Foundation announced that it will invest up to $8.4 million in SpliSense's Series B funding round to develop an antisense oligonucleotide therapy for people with cystic fibrosis who have splicing mutations and potentially other rare mutations.

Study reaffirms the Foundation’s commitment to advance solutions to the growing challenge of antibiotic resistance